Miguel Bronchud: Lung Cancer screening with low-dose computed tomography – where do we go from here?
Miguel Bronchud, Co-Founder & Advisory Board at Regenerative Medicine Solutions, shared a post on LinkedIn:
“Lung cancer screening– at present, only 5% or less of the highest risk groups in the USA and most European countries accept low dose computed tomography for early detection or screening ?
So – where do we go from here?
Lung cancer screening with low-dose computed tomography—where do we go from here?
Authors: Ashley Elizabeth Prosper, Yannan Lin, Denise R Aberle.
Cancer prevention and screening activities were the main contributors to reductions in mortality due to the most common cancers in the US over the past 45 years.
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
Authors: Katrina A. B. Goddard, et al.
And according to the above authors, 13 years following the publication of the National Lung Screening Trial (NLST) demonstrating a 20% reduction in lung cancer death for smokers screened with low-dose computed tomography, much work remains to be done.
A 2013 recommendation from the US Preventative Services Task Force (USPSTF) endorsed lung cancer screening for individuals aged 55-80 years with a 30-pack-year smoking history, currently smoking, or within 15 years of cessation- mandating coverage by private insurers. A year later, the USA Centers for Medicare and Medicaid Services announced a national coverage decision for beneficiaries aged 55-77 years, with smoking requirements mirroring the USPSTF.
Despite compelling data on lung cancer mortality reduction in clinical trials, and insurance coverage, lung cancer screening suffers from poor uptake in the USA and also in European countries.
This is in spite lung cancer is (for example) the biggest cancer killer including in women, well above average numbers of deaths due to breast cancers.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023